UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER, INC. and SAMSUNG BIOEPIS CO., LTD.,¹ Petitioners,

v.

GENENTECH, INC., Patent Owner,

_....

IPR2017-01489 Patent No. 6,407,213

PETITIONER PFIZER'S UPDATED MANDATORY NOTICES

¹ Samsung Bioepis Co., Ltd.'s IPR2017-02140 has been joined with this proceeding. (IPR2017-02140, Paper 40.)



In accordance with 37 C.F.R. §§ 42.8(a)(3), (b)(2) and (b)(3), Petitioner Pfizer hereby submits the following updated mandatory notices:

A. 37 C.F.R. § 42.8(b)(2): Related Matters

Petitioner concurrently filed an IPR petition for claims of U.S. Patent No. 6,407,213 (IPR2017-01488).

The '213 patent is the subject of two earlier IPR proceedings filed by third-party Mylan Pharmaceuticals Inc.: IPR2016–01693 and IPR2016–01694. These proceedings were terminated by the Board on March 10, 2017 after the parties filed a Joint Motion to Terminate. Paper No. 24, IPR2016–01693; Paper No. 23, IPR2016–01694 (March 10, 2017).

The '213 patent is also the subject of IPR2017-01373, IPR2017-01374, IPR2017-02031, IPR2017-02032, IPR2017-02139, and IPR2017-02140. Petitioner is not a party to those proceedings.

The '213 patent is also at issue in Amgen Inc v. Genentech, Inc. et al., No. 2-17-cv-07349 (C.D. Cal.); Genentech, Inc. et al. v. Amgen Inc., No. 1-17-cv-01407 (D. Del.); Genentech, Inc. et al. v. Amgen Inc., No. 1-17-cv-01471 (D. Del.); Celltrion, Inc. et al. v. Genentech, Inc. et al., No. 3-18-cv-00274 (N.D. Cal.); Genentech, Inc. et al. v. Celltrion, Inc. et al., No. 1-18-cv-00095 (D. Del.); Genentech, Inc. et al. v. Amgen, Inc., No. 1-18-cv-00924 (D. Del.); and Genentech,



IPR2017-01489

Petitioner Pfizer's Updated Mandatory Notices

Inc. et al. v. Celltrion, Inc. et al., No. 1-18-cv-01025(D. Del.). Petitioner is not a party to these proceedings.

Patent Owner has asserted the '213 patent against Petitioner in *Genentech*, *Inc. v. Pfizer, Inc.*, No. 1-17-cv-01672 (D. Del.), filed November 17, 2017.

Petitioner is not aware of any other judicial or administrative matters that would affect, or be affected by, a decision in the proceeding.

B. 37 C.F.R. § 42.8(b)(3): Lead and Back-Up Counsel

Lead Counsel	Back-up Counsel
Amanda Hollis (Reg. No. 55,629) amanda.hollis@kirkland.com	Benjamin A. Lasky (pro hac vice) benjamin.lasky@kirkland.com
Postal and Hand-Delivery Address: KIRKLAND & ELLIS LLP 300 North LaSalle Chicago, IL 60654 Telephone: (312) 862-2011 Facsimile: (312) 862-2200	Stefan Miller, Ph.D. (Reg. No. 57,623) stefan.miller@kirkland.com Sarah K. Tsou (<i>pro hac vice</i>) sarah.tsou@kirkland.com Mark C. McLennan (<i>pro hac vice</i>) mark.mclennan@kirkland.com
	Christopher J. Citro (<i>pro hac vice</i>) christopher.citro@kirkland.com
	Micah Rappazzo (Reg. No. 75,085) micah.rappazzo@kirkland.com
	Postal and Hand-Delivery Address:
	KIRKLAND & ELLIS LLP 601 Lexington Avenue New York, NY 10022 Telephone: (212) 446-4800



IPR2017-01489 Petitioner Pfizer's Updated Mandatory Notices

Lead Counsel	Back-up Counsel
	Facsimile: (212) 446-4900
	Sharick Naqi (pro hac vice pending)
	sharick.naqi@kirkland.com
	Postal and Hand-Delivery Address:
	KIRKLAND & ELLIS LLP
	300 North LaSalle
	Chicago, IL 60654
	Telephone: (312) 862-2011
	Facsimile: (312) 862-2200
	Karen Younkins (Reg. No. 67,554)
	(request for withdrawal pending)
	karen.younkins@kirkland.com
	Postal and Hand-Delivery Address:
	KIRKLAND & ELLIS LLP
	333 South Hope Street
	Los Angeles, CA 90071
	Telephone: (213) 680-8140
	Facsimile: (213) 680-8500

Date: July 12, 2018 Respectfully submitted,

/Amanda Hollis/

Amanda Hollis (Reg. No. 55,629) Attorney For Petitioner Pfizer, Inc.



CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing Updated Notices was served on July 12, 2018, via electronic service on lead and back-up counsel:

For Genentech, Inc.

david.cavanaugh@wilmerhale.com
lauren.blakely@wilmerhale.com
robert.gunther@wilmerhale.com
abrausa@durietangri.com
ddurie@durietangri.com
andrew.danford@wilmerhale.com
kevin.prussia@wilmerhale.com
lisa.pirozzolo@wilmerhale.com

For Samsung Bioepis Co., Ltd.:

ddrivas@whitecase.com sweingaertner@whitecase.com eric.majchrzak@whitecase.com athakore@whitecase.com

> <u>/Amanda Hollis/</u> Amanda Hollis

